Screener
Moderna MRNA Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Moderna’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001682852-26-000060
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 4,080 | 3,688 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2026 and December 31, 2025; 397 and 394 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 1,503 | 1,382 |
| Accumulated other comprehensive income | 25 | 45 |
| Retained earnings | 5,880 | 7,223 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Moderna's preferred stock, shares authorized?
- Moderna (MRNA) reported preferred stock, shares authorized of $162M in Q1 2026.
- How has Moderna's preferred stock, shares authorized changed year-over-year?
- Moderna's preferred stock, shares authorized decreased by 0.0% year-over-year, from $162M to $162M.
- What is the long-term trend for Moderna's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Moderna's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $162M to $162M.
Ask your AI about Moderna's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude